Rhythm Pharmaceuticals, Inc. (RYTM)

Market Cap	7.49B
Revenue (ttm)	174.33M
Net Income (ttm)	-197.71M
Shares Out	66.74M
EPS (ttm)	-3.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	228,112
Open	111.72
Previous Close	112.27
Day's Range	111.01 - 112.91
52-Week Range	45.91 - 122.20
Beta	1.97
Analysts	Strong Buy
Price Target	128.31 (+14.29%)
Earnings Date	Nov 4, 2025

About RYTM

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 de...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 5, 2017
• Employees: 283
• Stock Exchange: NASDAQ
• Ticker Symbol: RYTM
• Website: https://rhythmtx.com

Financial Performance

In 2024, Rhythm Pharmaceuticals's revenue was $130.13 million, an increase of 68.06% compared to the previous year's $77.43 million. Losses were -$264.57 million, 43.3% more than in 2023.

Analyst Summary

According to 13 analysts, the average rating for RYTM stock is "Strong Buy." The 12-month stock price target is $128.31, which is an increase of 14.29% from the latest price.

Price Target

$128.31

(14.29% upside)

Analyst Consensus: Strong Buy